{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:02:19Z","timestamp":1789628539304,"version":"build-2803163510"},"reference-count":80,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Endocrinology & Metabolism"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.tem.2019.06.004","type":"journal-article","created":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T08:13:40Z","timestamp":1563783220000},"page":"590-602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["The Changing Clinical Spectrum of Hypophysitis"],"prefix":"10.1016","volume":"30","author":[{"given":"Sabrina","family":"Chiloiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ettore Domenico","family":"Capoluongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Tartaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Giampietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giustina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Pontecorvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"De Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tem.2019.06.004_bb0005","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ecl.2014.10.011","article-title":"Hypophysitis","volume":"44","author":"Fukuoka","year":"2015","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"10.1016\/j.tem.2019.06.004_bb0010","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11102-013-0498-9","article-title":"Hypophysitis due to IgG4-related disease responding to treatment with azathioprine: an alternative to corticosteroid therapy","volume":"17","author":"Caputo","year":"2014","journal-title":"Pituitary"},{"key":"10.1016\/j.tem.2019.06.004_bb0015","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/bpa.12068","article-title":"Update on hypophysitis and TTF-1 expressing sellar region masses","volume":"23","author":"Kleinschmidt-de Masters","year":"2013","journal-title":"Brain Pathol."},{"key":"10.1016\/j.tem.2019.06.004_bb0020","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3171\/jns.1989.71.5.0681","article-title":"Giant-cell granulomatous hypophysitis: a distinct clinicopathological entity","volume":"71","author":"Scanarini","year":"1989","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.tem.2019.06.004_bb0025","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s002340050357","article-title":"Idiopathic granulomatous hypophysitis: clinical and imaging features","volume":"39","author":"Vasile","year":"1997","journal-title":"Neuroradiology"},{"key":"10.1016\/j.tem.2019.06.004_bb0030","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF02738885","article-title":"Xanthomatous hypophysitis: a novel entity of obscure etiology","volume":"10","author":"Deodhare","year":"1999","journal-title":"Endocr. Pathol."},{"key":"10.1016\/j.tem.2019.06.004_bb0035","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00005792-198907000-00006","article-title":"Lymphocytic hypophysitis report of 3 new cases and review of the literature","volume":"68","author":"Cosman","year":"1989","journal-title":"Medicine"},{"key":"10.1016\/j.tem.2019.06.004_bb0040","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1136\/jnnp.48.9.949","article-title":"A case of granulomatous hypophysitis with hypopituitarism and minimal pituitary enlargement","volume":"48","author":"Hassoun","year":"1985","journal-title":"J. Neurol. Neurosurg. Psych."},{"key":"10.1016\/j.tem.2019.06.004_bb0045","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF02739954","article-title":"Lymphocytic hypophysitis: light and microscopic findings and correlation to clinical appearance","volume":"9","author":"Fehn","year":"1998","journal-title":"Endocrine Pathol."},{"key":"10.1016\/j.tem.2019.06.004_bb0050","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s11102-017-0852-4","article-title":"A case series of atypical features of patients with biopsy-proven isolated IgG4-related hypophysitis and normal serum IgG4 levels","volume":"21","author":"Yuen","year":"2018","journal-title":"Pituitary."},{"key":"10.1016\/j.tem.2019.06.004_bb0055","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.5858\/arpa.2017-0257-RA","article-title":"IgG4-related disease: a reminder for practicing pathologists","volume":"141","author":"Weindorf","year":"2017","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.tem.2019.06.004_bb0060","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000446544","article-title":"An overview of diagnosis of primary autoimmune hypophysitis in a prospective single-center experience","volume":"104","author":"Chiloiro","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.tem.2019.06.004_bb0065","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s11102-018-0892-4","article-title":"Neuro-radiological features can predict hypopituitarism in primary autoimmune hypophysitis","volume":"21","author":"Tartaglione","year":"2018","journal-title":"Pituitary"},{"key":"10.1016\/j.tem.2019.06.004_bb0070","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000480086","article-title":"New molecular, biological, and immunological agents inducing hypophysitis","volume":"106","author":"Angelousi","year":"2018","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.tem.2019.06.004_bb0075","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.wneu.2018.03.086","article-title":"Lymphocytic hypophysitis secondary to ruptured rathke cleft cyst: case report and literature review","volume":"114","author":"Yang","year":"2018","journal-title":"World Neurosurg."},{"key":"10.1016\/j.tem.2019.06.004_bb0080","article-title":"Xanthogranulomatous hypophysitis: a rare and often mistaken pituitary lesion","volume":"2015","author":"Gopal-Kothandapani","year":"2015","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"10.1016\/j.tem.2019.06.004_bb0085","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1179\/acb.2010.027","article-title":"Panhypopituitarism apparently caused by hypophysitis masking a rapid development of a craniopharyngioma. A case report","volume":"65","author":"Joosen","year":"2010","journal-title":"Acta Clin. Belg."},{"key":"10.1016\/j.tem.2019.06.004_bb0090","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s11102-009-0187-x","article-title":"Pituitary and systemic autoimmunity in a case of intrasellar germinoma","volume":"14","author":"Gutenberg","year":"2011","journal-title":"Pituitary"},{"key":"10.1016\/j.tem.2019.06.004_bb0095","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4158\/EP.13.2.169","article-title":"Granulomatous adenohypophysitis after interferon and ribavirin therapy","volume":"13","author":"Tebben","year":"2007","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.tem.2019.06.004_bb0100","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/00042737-200606000-00019","article-title":"Central hypothyroidism and hypophysitis during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin","volume":"18","author":"Ridruejo","year":"2006","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2019.06.004_bb0105","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.amjmed.2018.09.004","article-title":"Granulomatosis with polyangiitis presenting as hypophysitis","volume":"132","author":"Chu","year":"2019","journal-title":"Am. J. Med."},{"key":"10.1016\/j.tem.2019.06.004_bb0110","first-page":"43","article-title":"Lymphocytic hypophysitis associated with Behcet\u2019s disease: a case report and review of the literature","volume":"39","author":"Tao","year":"2018","journal-title":"Neuro. Endocrinol. Lett."},{"key":"10.1016\/j.tem.2019.06.004_bb0115","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1155\/2010\/650692","article-title":"Sellar inflammatory mass with inflammatory bowel disease","volume":"24","author":"Freeman","year":"2010","journal-title":"Can. J. Gastroenterol."},{"key":"10.1016\/j.tem.2019.06.004_bb0120","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1186\/1471-2334-13-481","article-title":"Acute hypophysitis and hypopituitarism in early syphilitic meningitis in a HIV-infected patient: a case report","volume":"13","author":"Spinner","year":"2013","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.tem.2019.06.004_bb0125","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s13760-014-0373-0","article-title":"Brucella hypophysitis","volume":"115","author":"Ogul","year":"2015","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.tem.2019.06.004_bb0130","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11154-018-9480-1","article-title":"Primary hypophysitis and other autoimmune disorders of the sellar and suprasellar regions","volume":"19","author":"Gubbi","year":"2018","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.tem.2019.06.004_bb0135","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4158\/EP14202.CR","article-title":"Protracted and aggressive variant of lymphocytic hypophysitis with mammillary body involvement and cognitive disfunction","volume":"20","author":"Dow","year":"2014","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.tem.2019.06.004_bb0140","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.autrev.2014.01.021","article-title":"Diagnosis and classification of autoimmune hypophysitis","volume":"12","author":"Falorni","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.tem.2019.06.004_bb0145","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","author":"Albarel","year":"2015","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2019.06.004_bb0150","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypo- physitis: a retrospective cohort study","volume":"21","author":"Min","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tem.2019.06.004_bb0155","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2019.06.004_bb0160","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tem.2019.06.004_bb0165","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2217\/imt-2017-0024","article-title":"The future of immune checkpoint cancer therapy after PD-1 and CTLA-4","volume":"9","author":"Hahn","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.tem.2019.06.004_bb0170","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.tem.2019.06.004_bb0175","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/EJE-17-0810","article-title":"The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma","volume":"178","author":"Scott","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2019.06.004_bb0180","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor- related hypophysitis and endocrine dysfunction: clinical review","volume":"85","author":"Joshi","year":"2016","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.tem.2019.06.004_bb0185","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.tem.2019.06.004_bb0190","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med."},{"key":"10.1016\/j.tem.2019.06.004_bb0195","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40425-014-0035-z","article-title":"Ipilimumab in patients with melanoma and autoimmune disease","volume":"2","author":"Kyi","year":"2014","journal-title":"J. Immunother. Cancer."},{"key":"10.1016\/j.tem.2019.06.004_bb0200","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00262-014-1607-y","article-title":"Successful treatment with ipilimumab and interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease","volume":"63","author":"Pedersen","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.tem.2019.06.004_bb0205","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.tem.2019.06.004_bb0210","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdt107","article-title":"Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I\/II study","volume":"24","author":"Slovin","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tem.2019.06.004_bb0215","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tem.2019.06.004_bb0220","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1634\/theoncologist.4-5-370","article-title":"T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review","volume":"4","author":"Mackall","year":"1999","journal-title":"Oncologist"},{"key":"10.1016\/j.tem.2019.06.004_bb0225","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2217\/fon.15.222","article-title":"Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis","volume":"12","author":"Abdel-Rahman","year":"2016","journal-title":"Future Oncol."},{"key":"10.1016\/j.tem.2019.06.004_bb0230","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/cen.13566","article-title":"Human leucocyte antigens coeliac haplotypes and primary autoimmune hypophysitis in caucasian patients","volume":"88","author":"Chiloiro","year":"2018","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.tem.2019.06.004_bb0235","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11102-013-0550-9","article-title":"Primary (autoimmune) hypophysitis: a single centre experience","volume":"18","author":"Khare","year":"2015","journal-title":"Pituitary"},{"key":"10.1016\/j.tem.2019.06.004_bb0240","doi-asserted-by":"crossref","first-page":"R275","DOI":"10.1530\/EJE-17-0505","article-title":"Diagnosis of endocrine disease: primary empty sella: a comprehensive review","volume":"177","author":"Chiloiro","year":"2017","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2019.06.004_bb0245","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1210\/jc.2015-2146","article-title":"Treatment of primary hypophysitis in Germany","volume":"100","author":"Honegger","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2019.06.004_bb0250","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11102-016-0769-3","article-title":"Lymphocytic hypophysitis: modern day management with limited role for surgery","volume":"20","author":"Kyriacou","year":"2017","journal-title":"Pituitary."},{"key":"10.1016\/j.tem.2019.06.004_bb0255","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/apm.12603","article-title":"Granulomatous and lymphocytic hypophysitis \u2013 are they immunologically distinct?","volume":"124","author":"Rao","year":"2016","journal-title":"APMIS"},{"key":"10.1016\/j.tem.2019.06.004_bb0260","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1530\/EJE-17-0123","article-title":"Diabetes insipidus is an unfavorable prognostic factor for response to glucocorticoids in patients with autoimmune hypophysitis","volume":"177","author":"Lupi","year":"2017","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2019.06.004_bb0265","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1055\/s-0044-101036","article-title":"Clinical, endocrine and imaging characteristics of patients with primary hypophysitis","volume":"50","author":"Angelousi","year":"2018","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.tem.2019.06.004_bb0270","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.tem.2019.06.004_bb0275","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"(2016) Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.tem.2019.06.004_bb0280","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/bpa.12459","article-title":"IgG4-related hypophysitis in highly prevalent among cases of histologically confirmed hypophysitis","volume":"27","author":"Bernreuther","year":"2017","journal-title":"Brain Pathol."},{"key":"10.1016\/j.tem.2019.06.004_bb0285","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s40618-015-0301-z","article-title":"Ipilimumab-induced hypophysitis: review of the literature","volume":"38","author":"Araujo","year":"2015","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.tem.2019.06.004_bb0290","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11102-013-0510-4","article-title":"Idiopathic granulomatous hypophysitis: a systematic review of 82 cases in the literature","volume":"17","author":"Hunn","year":"2014","journal-title":"Pituitary"},{"key":"10.1016\/j.tem.2019.06.004_bb0295","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/jc.2016-2118","article-title":"Hormonal replacement in hypopituitarism in adults: an Endocrine Society Clinical Practice Guideline","volume":"101","author":"Fleseriu","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2019.06.004_bb0300","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1089\/thy.2014.0028","article-title":"Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement","volume":"24","author":"Jonklaas","year":"2014","journal-title":"Thyroid"},{"key":"10.1016\/j.tem.2019.06.004_bb0305","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.tem.2019.06.004_bb0310","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1210\/jc.2015-2236","article-title":"Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline","volume":"100","author":"Stuenkel","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2019.06.004_bb0315","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1530\/EJE-14-0824","article-title":"Extensive expertise in endocrinology: adrenal crisis","volume":"172","author":"Allolio","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2019.06.004_bb0320","first-page":"349","article-title":"Central diabetes insipidus","volume":"78","author":"Arima","year":"2016","journal-title":"Nagoya J. Med. Sci."},{"key":"10.1016\/j.tem.2019.06.004_bb0325","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jchemneu.2018.02.008","article-title":"Estrogen-induced neuroimmunomodulation as facilitator of and barrier to reproductive aging in brain and lymphoid organs","volume":"95","author":"ThyagaRajan","year":"2019","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.tem.2019.06.004_bb0330","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1007\/s10067-016-3330-x","article-title":"Hypogonadism and the risk of rheumatic autoimmune disease","volume":"35","author":"Baillargeon","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.tem.2019.06.004_bb0335","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1210\/jc.2018-01021","article-title":"Hypophysitis outcome and factors predicting responsiveness to glucocorticoid therapy: a prospective and double-arm study","volume":"103","author":"Chiloiro","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2019.06.004_bb0340","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EC-18-0068","article-title":"Acute management of the endocrine complications of checkpoint inhibitor therapy","volume":"7","author":"Higham","year":"2018","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.tem.2019.06.004_bb0345","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s12020-014-0199-9","article-title":"Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports","volume":"47","author":"Marlier","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.tem.2019.06.004_bb0350","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/cen.13354","article-title":"Primary lymphocytic hypophysitis: clinical characteristics and treatment of 50 cases in a single centre in China over 18 years","volume":"87","author":"Wang","year":"2017","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.tem.2019.06.004_bb0355","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.tem.2019.06.004_bb0360","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1210\/jc.2013-1912","article-title":"From Japan with love: another tessera in the hypophysitis mosaic","volume":"98","author":"Caturegli","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2019.06.004_bb0365","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/cam4.1145","article-title":"Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists","volume":"6","author":"Illouz","year":"2017","journal-title":"Cancer Med."},{"key":"10.1016\/j.tem.2019.06.004_bb0370","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s11102-016-0736-z","article-title":"Revisitation of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects","volume":"19","author":"Bellastella","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.tem.2019.06.004_bb0375","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1586\/17446651.2014.913979","article-title":"Rituximab-induced remission of autoimmune hypophysitis and primary immune thrombocytopenia in a patient with autoimmune polyendocrine syndrome type 4","volume":"9","author":"De Bellis","year":"2014","journal-title":"Expert. Rev. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2019.06.004_bb0380","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00296-019-04272-1","article-title":"Tolerability and safety of long-term rituximab treatment in systemic inflammatory and autoimmune diseases","volume":"39","author":"Vikse","year":"2019","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.tem.2019.06.004_bb0385","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2019.06.004_bb0390","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2019.06.004_bb0395","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.bulcan.2019.02.003","article-title":"Immunotherapy-induced endocrinopathies: Insights from the 2018 French Endocrine Society Guidelines","volume":"106","author":"Castinetti","year":"2019","journal-title":"Bull. Cancer"},{"key":"10.1016\/j.tem.2019.06.004_bb0400","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ando.2018.07.008","article-title":"Expert opinion on pituitary complications in immunotherapy","volume":"79","author":"Briet","year":"2018","journal-title":"Ann. Endocrinol. (Paris)"}],"container-title":["Trends in Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276019301213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276019301213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:38:55Z","timestamp":1760906335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043276019301213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":80,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1043276019301213"],"URL":"https:\/\/doi.org\/10.1016\/j.tem.2019.06.004","relation":{},"ISSN":["1043-2760"],"issn-type":[{"value":"1043-2760","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Changing Clinical Spectrum of Hypophysitis","name":"articletitle","label":"Article Title"},{"value":"Trends in Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tem.2019.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}